Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Neurologica Belgica
Published in: Acta Neurologica Belgica 2/2019

01-06-2019 | Vagus Nerve Stimulation | Review article

The current and emerging therapeutic approaches in drug-resistant epilepsy management

Authors: Amir Mehdizadeh, Mohammad Barzegar, Sohrab Negargar, Azita Yahyavi, Sina Raeisi

Published in: Acta Neurologica Belgica | Issue 2/2019

Login to get access

Abstract

Epilepsy is a neurologic disorder consisting of recurrent spontaneous seizures. Antiepileptic drugs administration is the most commonly used therapeutic strategy in the management of epilepsy. However, 20–30% of epilepsy patients have seizure episodes that are not controlled by these medicines (drug-resistant epilepsy). The management of drug-resistant epilepsy, especially in the children, is challenging and can cause economic and social problems, and lower the patients’ quality of life, cognition, and mood. Several therapeutic approaches for drug-resistant epilepsy are available including surgical methods, neurostimulation treatments, and diet therapies which lead to diminishing the epileptic seizures. An increasing number of novel and potential therapeutic approaches such as gene therapy, gene editing, cell therapy, exosome therapy, and molecular network targeting have also been explored. The present study is aimed to review these current and emerging therapeutic approaches for drug-resistant epilepsy.
Literature
1.
Hodges SL, Lugo JN (2018) Wnt/β-catenin signaling as a potential target for novel epilepsy therapies. Epilepsy Res 146:9–16PubMedCrossRef
2.
Nunes ML, Appel CC, da Costa JC (2003) Apparent life-threatening episodes as the first manifestation of epilepsy. Clin Pediatr 42(1):19–22CrossRef
3.
Barzegar M, Mahdavi M, Behbehani AG, Tabrizi A (2015) Refractory convulsive status epilepticus in children: etiology, associated risk factors and outcome. Iran J Child Neurol 9(4):24PubMedPubMedCentral
4.
Papandreou D, Pavlou E, Kalimeri E, Mavromichalis I (2006) The ketogenic diet in children with epilepsy. Br J Nutr 95(1):5–13PubMedCrossRef
5.
Cunnane S, Musa K, Ryan M, Whiting S, Fraser D (2002) Potential role of polyunsaturates in seizure protection achieved with the ketogenic diet. Prostaglandins Leukot Essent Fatty Acids 67(2–3):131–135PubMedCrossRef
6.
Giussani G, Cricelli C, Mazzoleni F, Cricelli I, Pasqua A, Pecchioli S, Lapi F, Beghi E (2014) Prevalence and incidence of epilepsy in Italy based on a nationwide database. Neuroepidemiology 43(3–4):228–232PubMedCrossRef
7.
Lauritzen F, Eid T, Bergersen LH (2015) Monocarboxylate transporters in temporal lobe epilepsy: roles of lactate and ketogenic diet. Brain Struct Funct 220(1):1–12PubMedCrossRef
8.
Kobau R, Zahran H, Thurman DJ, Zack MM, Henry TR, Schachter SC, Price PH (2008) Epilepsy surveillance among adults–19 states, behavioral risk factor surveillance system, 2005. MMWR Surveill Summ 57(6):1–20PubMed
9.
Mohanraj R, Brodie M (2006) Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 13(3):277–282PubMedCrossRef
10.
Campos G, Fortuna A, Falcão A, Alves G (2018) In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy. Epilepsy Res 146:63–86PubMedCrossRef
11.
Liu X, Han Q (2015) Risk factors on health-related quality of life in children with epilepsy. Clin Pediatr 54(14):1334–1338CrossRef
12.
Valizadeh L, Barzegar M, Akbarbegloo M, Zamanzadeh V, Rahiminia E, Ferguson C (2013) The relationship between psychosocial care and attitudes toward illness in adolescents with epilepsy. Epilepsy Behav 27(1):267–271PubMedCrossRef
13.
Cottrell L, Khan A (2005) Impact of childhood epilepsy on maternal sleep and socioemotional functioning. Clin Pediatr 44(7):613–616CrossRef
14.
Boison D (2007) Cell and gene therapies for refractory epilepsy. Curr Neuropharmacol 5(2):115–125PubMedCrossRef
15.
16.
17.
18.
Prideaux L, Barton S, Maixner W, Harvey AS (2018) Potential delays in referral and assessment for epilepsy surgery in children with drug-resistant, early-onset epilepsy. Epilepsy Res 143:20–26PubMedCrossRef
19.
Lukmanji S, Altura KC, Rydenhag B, Malmgren K, Wiebe S, Jetté N (2018) Accuracy of an online tool to assess appropriateness for an epilepsy surgery evaluation–A population-based Swedish study. Epilepsy Res 145:140–144PubMedCrossRef
20.
Ventureyra EC, Higgins MJ (1993) Complications of epilepsy surgery in children and adolescents. Pediatr Neurosurg 19(1):40–56PubMedCrossRef
21.
Olson DM (2001) Evaluation of children for epilepsy surgery. Pediatric Neurosurg 34(3):159–165CrossRef
22.
Nordli DR, Kelley KR (2001) Selection and evaluation of children for epilepsy surgery. Pediatric Neurosurg 34(1):1–12CrossRef
23.
Pati S, Alexopoulos AV (2010) Pharmacoresistant epilepsy: from pathogenesis to current and emerging therapies. Cleve Clin J Med 77(7):457–567PubMedCrossRef
24.
Rajesh P, Bejoy T, VS CP, Kesavadas C, Ashalatha R, Aley A (2018) Hippocampal activations in mesial temporal lobe epilepsy due to hippocampal sclerosis-an observational study on intramural encoding-delayed recall paradigms using task-based memory fMRI. Epilepsy Res 145:31–39PubMedCrossRef
25.
Schusse CM, Smith K, Drees C (2018) Outcomes after hemispherectomy in adult patients with intractable epilepsy: institutional experience and systematic review of the literature. J Neurosurg 128(3):853–861PubMedCrossRef
26.
Griessenauer CJ, Salam S, Hendrix P, Patel DM, Tubbs RS, Blount JP, Winkler PA (2015) Hemispherectomy for treatment of refractory epilepsy in the pediatric age group: a systematic review. J Neurosurg Pediatr 15(1):34–44PubMedCrossRef
27.
Beleza P (2009) Refractory epilepsy: a clinically oriented review. Eur Neuro 62(2):65–71CrossRef
28.
Panebianco M, Rigby A, Weston J, Marson AG (2015) Vagus nerve stimulation for partial seizures. Cochrane Database Syst Rev 3(4):CD002896
29.
Ben-Menachem E, Revesz D, Simon B, Silberstein S (2015) Surgically implanted and non-invasive vagus nerve stimulation: a review of efficacy, safety and tolerability. Eur J Neurol 22(9):1260–1268PubMedPubMedCentralCrossRef
30.
Finetti C (2015) P90. Transcutaneous vagus nerve stimulation (t-VNS) in a child with dravet syndrome–a case report. Clin Neurophysiol 126(8):e147CrossRef
31.
Amar AP, Levy ML, McComb JG, Apuzzo ML (2001) Vagus nerve stimulation for control of intractable seizures in childhood. Pediatr Neurosurg 34(4):218–223PubMedCrossRef
32.
Schulze-Bonhage A (2017) Brain stimulation as a neuromodulatory epilepsy therapy. Seizure 44:169–175PubMedCrossRef
33.
Wilder R (1921) The effects of ketonemia on the course of epilepsy. In Mayo Clin Proc 2:307–308
34.
35.
Gonzalez FL, Osorio XR, Rein AG-N, Martinez MC, Fernandez JS, Haba VV, Pedraza AD, Cerdá JM (2015) Drug-resistant epilepsy: definition and treatment alternatives. Neurologia 30(7):439–446CrossRef
36.
Rezaei S, Kavoosi M, Badv RS, Mohammadi M, Zamani GR, Ashrafi MR, Yekaninejad MS, Mahmoudi M, Crossen K, Tehranian A (2017) The influence of ketogenic diet on liver function in children and adolescents with intractable epilepsy. J Compr Pediatr 8(3):e12609
37.
Kossoff EH, Shields WD (2014) Nonpharmacologic care for patients with Lennox-Gastaut syndrome: Ketogenic diets and vagus nerve stimulation. Epilepsia 55(s4):29–33PubMedCrossRef
38.
Spulber G, Spulber S, Hagenäs L, Åmark P, Dahlin M (2009) Growth dependence on insulin-like growth factor-1 during the ketogenic diet. Epilepsia 50(2):297–303PubMedCrossRef
39.
40.
Miranda MJ, Turner Z, Magrath G (2012) Alternative diets to the classical ketogenic diet—Can we be more liberal? Epilepsy Res 100(3):278–285PubMedCrossRef
41.
Katyal NG, Koehler AN, McGhee B, Foley CM, Crumrine PK (2000) The ketogenic diet in refractory epilepsy: the experience of Children’s Hospital of Pittsburgh. Clin Pediatr 39(3):153–159CrossRef
42.
Milder J, Patel M (2012) Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res 100(3):295–303PubMedCrossRef
43.
Sudha K, Rao AV, Rao A (2001) Oxidative stress and antioxidants in epilepsy. Clin Chim Acta 303(1–2):19–24PubMedCrossRef
44.
Shin E-J, Jeong JH, Chung YH, Kim W-K, Ko K-H, Bach J-H, Hong J-S, Yoneda Y, Kim H-C (2011) Role of oxidative stress in epileptic seizures. Neurochem Int 59(2):122–137PubMedPubMedCentralCrossRef
45.
Rao G, Mashkouri S, Aum D, Marcet P, Borlongan CV (2017) Contemplating stem cell therapy for epilepsy-induced neuropsychiatric symptoms. Neuropsychiatr Dis Treat 13:585–596PubMedPubMedCentralCrossRef
46.
Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ (2013) Progress in gene therapy for neurological disorders. Nat Rev Neuro 9(5):277–291CrossRef
47.
48.
49.
Noè F, Pool A-H, Nissinen J, Gobbi M, Bland R, Rizzi M, Balducci C, Ferraguti F, Sperk G, During MJ (2008) Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 131(6):1506–1515PubMedCrossRef
50.
Raol YH, Lund IV, Bandyopadhyay S, Zhang G, Roberts DS, Wolfe JH, Russek SJ, Brooks-Kayal AR (2006) Enhancing GABAA receptor α1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J Neurosci 26(44):11342–11346PubMedPubMedCentralCrossRef
51.
Haberman RP, Samulski RJ, McCown TJ (2003) Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med 9(8):1076–1080PubMedCrossRef
52.
Richichi C, Lin E-JD, Stefanin D, Colella D, Ravizza T, Grignaschi G, Veglianese P, Sperk G, During MJ, Vezzani A (2004) Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 24(12):3051–3059PubMedPubMedCentralCrossRef
53.
Kanter-Schlifke I, Georgievska B, Kirik D, Kokaia M (2007) Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol Ther 15(6):1106–1113PubMedCrossRef
54.
Paradiso B, Zucchini S, Su T, Bovolenta R, Berto E, Marconi P, Marzola A, Mora GN, Fabene PF, Simonato M (2011) Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. Epilepsia 52(3):572–578PubMedCrossRef
55.
Paradiso B, Marconi P, Zucchini S, Berto E, Binaschi A, Bozac A, Buzzi A, Mazzuferi M, Magri E, Mora GN (2009) Localized delivery of fibroblast growth factor–2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci USA 106(17):7191–7196PubMedCrossRefPubMedCentral
56.
Mollanoori H, Teimourian S (2018) Therapeutic applications of CRISPR/Cas9 system in gene therapy. Biotechnol Lett 40:907–914PubMedCrossRef
57.
Savić N, Schwank G (2016) Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res 168:15–21PubMedCrossRef
58.
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816–821PubMedPubMedCentralCrossRef
59.
Wykes R, Lignani G (2018) Gene therapy and editing: Novel potential treatments for neuronal channelopathies. Neuropharmacology 132:108–117PubMedCrossRef
60.
61.
Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M, Zhang F (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33(1):102–106PubMedCrossRef
62.
63.
Rossi F, Cattaneo E (2002) Neural stem cell therapy for neurological diseases: dreams and reality. Nat Rev Neurosci 3(5):401PubMedCrossRef
64.
Luarte A, Bátiz LF, Wyneken U, Lafourcade C (2016) Potential therapies by stem cell-derived exosomes in CNS diseases: focusing on the neurogenic niche. Stem Cells Int 2016:5736059PubMedPubMedCentralCrossRef
65.
66.
Kalani A, Tyagi A, Tyagi N (2014) Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics. Mol Neurobiol 49(1):590–600PubMedCrossRef
67.
van Niel G, D’Angelo G, Raposo G (2018) Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19(4):213–228PubMedCrossRef
68.
Tiwari D, Peariso K, Gross C (2018) MicroRNA-induced silencing in epilepsy: opportunities and challenges for clinical application. Dev Dyn 247(1):94–110PubMedCrossRef
69.
Henshall DC, Hamer HM, Pasterkamp RJ, Goldstein DB, Kjems J, Prehn JH, Schorge S, Lamottke K, Rosenow F (2016) MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol 15(13):1368–1376PubMedCrossRef
70.
71.
Zeng L-H, Rensing NR, Wong M (2009) The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 29(21):6964–6972PubMedPubMedCentralCrossRef
72.
Xiao Z, Peng J, Gan N, Arafat A, Yin F (2016) Interleukin-1β plays a pivotal role via the PI3K/Akt/mTOR signaling pathway in the chronicity of mesial temporal lobe epilepsy. Neuroimmunomodulation 23(5–6):332–344PubMedCrossRef
73.
Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN (2013) Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 74(5):679–687PubMedCrossRef
74.
Qu Z, Su F, Qi X, Sun J, Wang H, Qiao Z, Zhao H, Zhu Y (2017) Wnt/β-catenin signalling pathway mediated aberrant hippocampal neurogenesis in kainic acid-induced epilepsy. Cell Biochem Funct 35(7):472–476PubMedCrossRef
75.
Metadata
Title
The current and emerging therapeutic approaches in drug-resistant epilepsy management
Authors
Amir Mehdizadeh
Mohammad Barzegar
Sohrab Negargar
Azita Yahyavi
Sina Raeisi
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Acta Neurologica Belgica / Issue 2/2019
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-019-01120-8

Other articles of this Issue 2/2019

Acta Neurologica Belgica 2/2019 Go to the issue

Neuro-Images

Magnetic resonance imaging features of gelatinous pseudocysts in cryptococcal meningoencephalitis

Neuro-Images

Central-variant posterior reversible encephalopathy syndrome in a young patient with systemic lupus erythematosus

Original Article

Sleep during low-frequency repetitive transcranial magnetic stimulation is associated with functional improvement in upper limb hemiparesis after stroke

Original article

Nocebo effect in myasthenia gravis: systematic review and meta-analysis of placebo-controlled clinical trials

Original article

Active neuroborreliosis or inflammation: are the diagnostic guidelines at stake?

Neuro-Images

Psychotic polyembolokoilamania secondary to left parietal lobe glioblastoma